285 related articles for article (PubMed ID: 21093374)
1. Mammographic surveillance in women younger than 50 years who have a family history of breast cancer: tumour characteristics and projected effect on mortality in the prospective, single-arm, FH01 study.
FH01 collaborative teams
Lancet Oncol; 2010 Dec; 11(12):1127-34. PubMed ID: 21093374
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of mammographic surveillance services in women aged 40-49 years with a moderate family history of breast cancer: a single-arm cohort study.
Duffy SW; Mackay J; Thomas S; Anderson E; Chen TH; Ellis I; Evans G; Fielder H; Fox R; Gui G; Macmillan D; Moss S; Rogers C; Sibbering M; Wallis M; Warren R; Watson E; Whynes D; Allgood P; Caunt J
Health Technol Assess; 2013 Mar; 17(11):vii-xiv, 1-95. PubMed ID: 23489892
[TBL] [Abstract][Full Text] [Related]
3. Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT.
Duffy S; Vulkan D; Cuckle H; Parmar D; Sheikh S; Smith R; Evans A; Blyuss O; Johns L; Ellis I; Sasieni P; Wale C; Myles J; Moss S
Health Technol Assess; 2020 Oct; 24(55):1-24. PubMed ID: 33141657
[TBL] [Abstract][Full Text] [Related]
4. Screening mammography for women aged 40 to 49 years at average risk for breast cancer: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2007; 7(1):1-32. PubMed ID: 23074501
[TBL] [Abstract][Full Text] [Related]
5. MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial.
Saadatmand S; Geuzinge HA; Rutgers EJT; Mann RM; de Roy van Zuidewijn DBW; Zonderland HM; Tollenaar RAEM; Lobbes MBI; Ausems MGEM; van 't Riet M; Hooning MJ; Mares-Engelberts I; Luiten EJT; Heijnsdijk EAM; Verhoef C; Karssemeijer N; Oosterwijk JC; Obdeijn IM; de Koning HJ; Tilanus-Linthorst MMA;
Lancet Oncol; 2019 Aug; 20(8):1136-1147. PubMed ID: 31221620
[TBL] [Abstract][Full Text] [Related]
6. Mammography service screening and breast cancer mortality in New Zealand: a National Cohort Study 1999-2011.
Morrell S; Taylor R; Roder D; Robson B; Gregory M; Craig K
Br J Cancer; 2017 Mar; 116(6):828-839. PubMed ID: 28183141
[TBL] [Abstract][Full Text] [Related]
7. Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial.
Saadatmand S; Rutgers EJ; Tollenaar RA; Zonderland HM; Ausems MG; Keymeulen KB; Schlooz-Vries MS; Koppert LB; Heijnsdijk EA; Seynaeve C; Verhoef C; Oosterwijk JC; Obdeijn IM; de Koning HJ; Tilanus-Linthorst MM
BMC Cancer; 2012 Oct; 12():440. PubMed ID: 23031619
[TBL] [Abstract][Full Text] [Related]
8. Earlier detection of breast cancer by surveillance of women at familial risk.
Tilanus-Linthorst MM; Bartels CC; Obdeijn AI; Oudkerk M
Eur J Cancer; 2000 Mar; 36(4):514-9. PubMed ID: 10717529
[TBL] [Abstract][Full Text] [Related]
9. Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial.
Duffy SW; Vulkan D; Cuckle H; Parmar D; Sheikh S; Smith RA; Evans A; Blyuss O; Johns L; Ellis IO; Myles J; Sasieni PD; Moss SM
Lancet Oncol; 2020 Sep; 21(9):1165-1172. PubMed ID: 32800099
[TBL] [Abstract][Full Text] [Related]
10. The challenge of evaluating annual mammography screening for young women with a family history of breast cancer.
FH01 Management Committee, Steering Committee and Collaborators
J Med Screen; 2006; 13(4):177-82. PubMed ID: 17217606
[TBL] [Abstract][Full Text] [Related]
11. Cancer screening with digital mammography for women at average risk for breast cancer, magnetic resonance imaging (MRI) for women at high risk: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(3):1-55. PubMed ID: 23074406
[TBL] [Abstract][Full Text] [Related]
12. The frequency of breast cancer screening: results from the UKCCCR Randomised Trial. United Kingdom Co-ordinating Committee on Cancer Research.
Breast Screening Frequency Trial Group
Eur J Cancer; 2002 Jul; 38(11):1458-64. PubMed ID: 12110490
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Mortality Among Participants of Women's Health Initiative Trials With Screening-Detected Breast Cancers vs Interval Breast Cancers.
Irvin VL; Zhang Z; Simon MS; Chlebowski RT; Luoh SW; Shadyab AH; Krok-Schoen JL; Tabung FK; Qi L; Stefanick ML; Schedin P; Jindal S
JAMA Netw Open; 2020 Jun; 3(6):e207227. PubMed ID: 32602908
[TBL] [Abstract][Full Text] [Related]
14. Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50 to 59 years.
Miller AB; Baines CJ; To T; Wall C
CMAJ; 1992 Nov; 147(10):1477-88. PubMed ID: 1423088
[TBL] [Abstract][Full Text] [Related]
15. Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial.
Moss SM; Wale C; Smith R; Evans A; Cuckle H; Duffy SW
Lancet Oncol; 2015 Sep; 16(9):1123-1132. PubMed ID: 26206144
[TBL] [Abstract][Full Text] [Related]
16. Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years.
Miller AB; Baines CJ; To T; Wall C
CMAJ; 1992 Nov; 147(10):1459-76. PubMed ID: 1423087
[TBL] [Abstract][Full Text] [Related]
17. One-view breast tomosynthesis versus two-view mammography in the Malmö Breast Tomosynthesis Screening Trial (MBTST): a prospective, population-based, diagnostic accuracy study.
Zackrisson S; Lång K; Rosso A; Johnson K; Dustler M; Förnvik D; Förnvik H; Sartor H; Timberg P; Tingberg A; Andersson I
Lancet Oncol; 2018 Nov; 19(11):1493-1503. PubMed ID: 30322817
[TBL] [Abstract][Full Text] [Related]
18. [Tailored Breast Screening Trial (TBST)].
Paci E; Mantellini P; Giorgi Rossi P; Falini P; Puliti D;
Epidemiol Prev; 2013; 37(4-5):317-27. PubMed ID: 24293498
[TBL] [Abstract][Full Text] [Related]
19. Effect of screening by clinical breast examination on breast cancer incidence and mortality after 20 years: prospective, cluster randomised controlled trial in Mumbai.
Mittra I; Mishra GA; Dikshit RP; Gupta S; Kulkarni VY; Shaikh HKA; Shastri SS; Hawaldar R; Gupta S; Pramesh CS; Badwe RA
BMJ; 2021 Feb; 372():n256. PubMed ID: 33627312
[TBL] [Abstract][Full Text] [Related]
20. Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials.
de Koning HJ; Boer R; Warmerdam PG; Beemsterboer PM; van der Maas PJ
J Natl Cancer Inst; 1995 Aug; 87(16):1217-23. PubMed ID: 7563167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
